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Background: Data on the effectiveness of second-line antiretroviral therapy (ART) in resource-limited countries of
Eastern Europe is limited. Objective of this study was to evaluate virological outcomes of second-line ART in Georgia.
Methods: We conducted retrospective analysis using routinely available program data. Study included adult HIV-infected
patients with confirmed HIV drug resistance, who were switched to second-line ART from August 2005 to December
2010. Patients were followed until July 1, 2011. Primary outcome was achievement of viral suppression. Demographic,
clinical, laboratory and adherence data were abstracted from medical and program records. Adherence was expressed as
percentage based on medication refill data, and was calculated as days supply of medications dispensed divided by days
between prescription fills. Predictors of primary outcome were assessed in modified Poisson regression analysis.
Results: A total of 84 patients were included in the study. Among them 71.4% were men and 62% had history of IDU. All
patients were receiving non-nucleoside reverse transcriptase based regimen as initial ART. The mean 6-month adherence
prior to virologic failure was 75%, with 31% of patients showing 100% adherence. All patients were switched to protease
inhibitor based regimens. Patients were followed for median 27 months. Over this period 9 (10.7%) patients died. Among
80 patients remaining alive at least 6 month after ART regimen switch, 72 (90%) patients ever reached undetectable viral
load. The mean first 6-month adherence on second-line treatment was 81%, with 47.5% of patients showing 100%
adherence. The proportion of patients achieving viral suppression after 6, 12, 24 and 36 months of second-line ART did
not vary significantly ranging from 79 to 83%. Percentage of IDUs achieving viral suppression ranged from 75% and 83%.
Factors associated with failure to achieve viral suppression at 6-months of second-line ART were: adherence <80% (Risk
ratio [RR] 5.09, 95% CI: 1.89-13.70) and viral load >100,000 at the time of treatment failure (RR 3.39, 95% CI: 1.46-7.89).
Conclusions: The study demonstrated favourable virological outcomes of the second-line ART in Georgia. Majority of
patients, including IDUs, achieved sustained virological response over 36 month period. The findings highlight the need
of improving adherence.
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The number of people receiving antiretroviral therapy
(ART) in resource limited settings is climbing rapidly.
At the end of 2012 estimated 9.7 million people in
low- and middle-income countries had access to ART,
representing 40-fold increase over the last decade [1].
As scale-up of ART continues growing number of* Correspondence: nc@aidscenter.ge
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article, unless otherwise stated.patients experience treatment failure increasing demand
on second-line regimens [2-4].
There is limited data on the use of second-line ART in
Eastern European region, where HIV epidemic is primarily
driven by injection drug users (IDU). Although region has
low ART coverage, the absolute number of persons acces-
sing the lifesaving therapy has been annually increasing
and reached nearly 200,000 in 2012 [1]. Better under-
standing of second-line ART delivery in the region will be
important to ensure its long-term effectiveness.
Georgia is an Eastern European nation located in the
Caucasus between Turkey and Russia. Similar to otherentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Patient characteristics at the time of virological
failure on initial ART (n = 84)
n = 84




Mode of HIV transmission, n (%)
Injection drug use 52 (61.9)
Heterosexual contact 28 (33.3)
Male-to-male sex 2 (2.4)
Blood recipient 2 (2.4)




History of TB 35 (41.7)
No history of TB 49 (58.3)
ART regimen at failure, n (%)
Zidovudine + Lamivudine + Efavirenz 39 (46.4)
Zidovudine + Lamivudine + Nevirapine 14 (16.7)
Abacavir + Lamivudine + Efavirenz 17 (20.2)
Abacavir + Lamivudine + Nevirapine 3 (3.6)
Stavudine + Lamivudine + Efavirenz 7 (8.3)
Stavudine + Lamivudine + Nevirapine 2 (2.4)
Tenofovir + Emtricitabine + Efavirenz 2 (2.4)
6-month adherence prior to failure, n (%)
<80% 36 (42.9)
80- < 100% 22 (26.2)
100% 26 (30.9)
Time to failure, median (IQR) 18 (12–34)
Viral load at failure, median copies/ml (IQR) 23600 (8365–126000)
Number of resistant mutations, median (IQR) 2 (1–4)
Drug class resistance, n (%)
Single class (NRTI or NNRTI) 12 (14.3)
Dual class (NRTI + NNRTI) 72 (85.7)
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been concentrated around IDUs, accounting for 55% of
total reported cases of HIV infection. Since 2004, through
the support from the Global Fund to Fight AIDS, Tuber-
culosis and Malaria Georgia has ensured universal access
to ART. UNAIDS estimates conform that Georgia has the
highest ART coverage in the region [1]. Previously we
showed that ART substantially reduced mortality and
increased survival in Georgia [5,6]. The objective of the
current study was to evaluate virologic outcomes of
second-line ART in the country.
Methods
We conducted retrospective analysis using routinely avail-
able program data. Study included adult (age ≥18 years)
HIV-infected patients enrolled in national HIV/AIDS treat-
ment and care program. Patients with confirmed HIV drug
resistance, who were switched to second-line ART regi-
mens from August 2005 to December 2010 were included
in the analysis. Patients were followed until July 1, 2011.
Georgia’s national HIV/AIDS treatment and care pro-
gram provides HIV related medical services to all diagnosed
HIV patients. The program is coordinated by the Infectious
Diseases, AIDS and Clinical Immunology Research Center
(IDACIRC), which is country’s referral institution for HIV
diagnosis, treatment and care. Patients receive services at
IDACIRC clinic and three dedicated regional facilities.
Provision of ART in Georgia is governed by national
HIV/AIDS treatment and care guidelines, which was first
developed in 2004. During the study period (2005–2010)
ART was recommended at CD4 count ≤200 cells/mm3.
The recommended initial regimen consisted of two nu-
cleoside reverse transcriptase inhibitors (NRTI) and one
non-nucleoside reverse transcriptase inhibitor (NNRTI).
Zidvudine (AZT) + lamivudine (3TC) has been preferred
NRTI component since 2004. Stavudine (d4T) was phased
out after 2007 revision of national guidelines, and was re-
placed by abacavir (ABC) + lamivudine (3TC) or tenofovir
(TDF) + emtricitabine (FTC). Efavirenz (EFV) has been
the preferred NNRTI with nevirapine (NVP) being recom-
mended as an alternative to EFV.
According to national guidelines follow-up of patients on
ART relied on regular monitoring of CD4 count and HIV
viral load. HIV drug resistance was performed routinely
among patients with virologic failure, defined as confirmed
plasma HIV RNA >400 copies/ml 6 months after starting
therapy or after undetectable viral load while on therapy.
Results of drug résistance testing were used for selection of
second-line therapy.
During the study period plasma HIV RNA levels were
measured using either Amplicor HIV-1 Monitor test,
version 1.5 (Roche Molecular Diagnostics, Germany) or
the real-time PCR assay COBAS TaqMan HIV-1 test
(Roche Molecular Diagnostics, Germany). For genotypicresistance testing the TruGene HIV-1 Genotyping Kit
was employed according to the manufacturer’s instruc-
tions using OpenGene DNA Sequencing System (Siemens
Medical Solutions Diagnostics, Germany). The Stanford
University algorithm (http://hivdb.stanford.edu/) were
used for resistance interpretation.
Demographic, epidemiological, clinical and laboratory
data were extracted from program and medical records.
Baseline characteristics were collected at the time point
when patient experienced virologic failure. Adherence was

















# patients with viral load <400 c/ml 63 53 39 21
Total# patients on follow-up 80 65 47 26
Time from ART regimen switch:
Figure 1 The proportion of patients achieving viral suppression after initiating second-line antiretroviral therapy.
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pensed divided by days between prescription fills. The pri-
mary outcome was proportion of patients achieving viral
suppression (<400 copies/ml) after the switch to second
line ART. Predictors of primary outcome were assessed in
modified Poisson regression analysis [7]. All statistical ana-
lyses were performed using SAS 9.2.
Study was approved by the Institutional Review Board
of IDACIRC.
Results
Table 1 summarizes characteristics of 84 patients included
in the analysis. Among them the majority were men
(71.4%) and 62% had history of IDU. At the time of viro-
logic failure on initial ART, all patients were receiving
NNRTI based regimen, and vast majority (77%) were on
EFV (77%). AZT+ 3TC was the most common NRTI back-
bone, prescribed to 63% of patients. The mean 6-month
medication refill adherence prior to virologic failure was
75%, with 31% of patients timely picking-up their prescrip-
tion. None of the patients had virus with resistance muta-
tions to PIs, and 86% had NRTI/NNRTI dual class-resistant
viruses. All patients were switched to PI-containing regi-
mens, including 62 (73.8%) to ritonavir boosted Lopinvair
(LPV/r)-based and 22 (26.2%) to ritonavir boosted Atazana-
vir (ATV/r)-based regimens.
Patients were followed for median 27 (Interquartile
range [IQR]: 13–41) months. Over this period 9 (10.7%)
patients died in median 6 (IQR: 2–8) months after treat-
ment switch, four of them died within 6 month period.
Among 80 patients remaining alive at least 6 month
after ART regimen switch, 72 (90%) patients ever achieved
viral suppression after median 7 (IQR: 5–10) months. The
mean first 6-month adherence on second-line treatment
was 81%, with 47.5% of patients showing 100% adherence.
The proportion of patients achieving viral suppressionafter 6, 12, 24 and 36 months of second-line ART did not
vary significantly ranging from 79 to 83% (Figure 1). Per-
centage of IDUs achieving viral suppression ranged from
75% and 83%. During the follow-up five patients met the
criteria of virologic failure and were tested for HIV drug
resistance. None of the strains evaluated carried major
PI mutations.
Factors associated with failure to achieve viral suppression
after 6 months of regimen modification were evaluated in
multivariate analysis. Lower adherence <80% (Risk ratio [RR]
5.09, 95% Confidence interval [CI]: 1.89-13.70) and viral load
of greater than 100,000 at the time of treatment failure (RR
3.39, 95% CI: 1.46-7.89) were significantly associated with de-
tectable viral load (Table 2). Neither gender nor mode of
HIV transmission showed association with the outcome.
Discussion
Findings of this analysis indicate that majority of patients
with HIV drug resistance in Georgia achieve and maintain
viral suppression after switching to second-line therapy. To
the best of our knowledge this is the first published study
that evaluated outcomes of second-line ART in Eastern
Europe, therefore regional comparisons cannot be made.
Early virologic outcomes seen in our study were generally
consistent with findings from other resource-limited coun-
tries, primarily from Africa and Asia, with approximately
80% of patients on second-line ART achieving viral sup-
pression at 6 and 12 months [8-12]. Recent meta-analysis
of 19 studies found that that proportion of patients achiev-
ing viral suppression dropped from 78% at 6 months to
62% at 36 months of starting second-line regimen [8].
However, there was substantially heterogeneity between
studies, with some studies reporting success rates of around
and more than 90% [13-16]. In our study more than 80% of
patients consistently had undetectable levels of viral load
after 6 months of second-line ART.
Table 2 Factors associated with failure to achieve viral suppression 6 months after switching ART regimen (n = 80)
Total N Detectable viral load
n (%) Bivariate Multivariate
RR (95% CI) RR (95% CI)
Age
<37 years 35 7 (20.0) 0.90 (0.38-2.12)
≥37 years 45 10 (22.2) 1
Sex
Men 57 13 (22.8) 1.31 (0.48-3.60) 0.50 (0.17-1.45)
Women 23 4 (17.4) 1 1
Mode of HIV transmission
IDU 49 12 (24.5) 1.52 (0.59-3.89) 1.34 (0.64-2.83)
non-IDU 31 5 (16.1) 1 1
HCV infection
anti-HCV+ 42 9 (21.4) 1.02 (0.44-2.37)
anti-HCV- 38 8 (21.1) 1
Tuberculosis
History of TB 31 6 (19.4) 0.86 (0.36-2.09)
No history of TB 49 11 (22.5) 1
Viral load at failure on initial ART
≥100,000 21 9 (42.9) 3.16 (1.40-7.12) 3.39 (1.46-7.89)
<100,000 59 8 (13.6) 1 1
ART regimen after switch
ATV/r-based 20 4 (20.0) 0.92 (0.34-2.51)
LPV/r-based 60 13 (21.7) 1
6-month adherence after regimen switch
<80% 19 10 (52.6) 5.01 (1.80-13.87) 5.09 (1.89-13.70)
80- < 100% 23 3 (13.0) 1.24 (0.30-5.05) 1.48 (0.36-6.12)
100% 38 4 (10.5) 1 1
Number of resistance mutations
>2 mutations 21 3 (14.3) 0.60 (0.19-1.89)
≤2 mutations 59 14 (23.7) 1
Drug class resistance
Single class (NRTI or NNRTI) 11 3 (27.3) 1.34 (0.46-3.93)
Dual class (NRTI + NNRTI) 69 14 (20.3) 1
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the strongest predictor of failure to achieve viral suppres-
sion after 6 months of second-line ART (RR 5.09, 95% CI:
1.89-13.70). There was no statistically significant difference
between adherence levels of 100% and 80- < 100%. Also,
none of five patients screened for HIV drug resistance after
failure of second-line ART harbored the viruses with major
PI mutations. These data confirm that ritonavir-boosted PI
regimens in Georgian settings are ‘forgiving’ as seen else-
where [17] and that non-adherence is the primary reason
of virologic failure, but not resistance. Similar findings were
reported by Murphy and colleagues [10]. Although overalladherence improved after treatment modification, efforts
are still needed to ensure high levels of adherence in a long
term in all patients.
The reported rates of mortality among patients on
second-line ART varied substantially, ranging from 3% to
16% [18-21]. In our study 11% of patients died over the
follow-up, including four patients died within 6 months
after the switch. It is unlikely that mortality in our study
was directly related to virologic failure to initial regimen.
Routine use of viral load in Georgia and low number of
drug resistance mutation at the time failure indicates that
regimens were modified timely. Analysis of causes of death
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mortality in our study. Six (67%) of 9 deaths reported were
attributable to non-AIDS related causes, including end
stage liver disease and cardiovascular disease.
Our study provides evidence that persons with history of
IDU can achieve optimal treatment outcomes. Percentage of
IDUs achieving viral suppression ranged from 75% and 83%
after initial treatment modification. Also, history of IDU was
not associated with virologic failure in multivariate analysis.
This has important implications for the Eastern European
region, where IDUs are often face barriers for accessing ART
[22]. Our study clearly shows that IDUs can achieve optimal
treatment outcomes and that no one should be withheld
from therapy. Factors that might have contributed to optimal
outcomes among persons with history of IDU include envir-
onment with free HIV-related medical care, availability of ad-
herence support services and methadone substation therapy.
Our study is subject to limitations. First this is the
small sample size, which limited statistical power and
generalizability of our findings. Also, we conducted retro-
spective analysis utilizing routinely available data, thus there
might have been unmeasured factors that influenced the out-
comes. We only had information on history of IDU, based
on HIV transmission category. Information on ongoing drug
abuse may have influenced comparisons. Viral load was mea-
sured by physician’s discretion and we extracted measure-
ments closest to the time intervals studied.
Conclusions
In conclusion, our study shows that second-line therapy
is effective in IDU-driven epidemic setting of Georgia.
More than 80% of patients, including those with history
of IDU, maintained viral suppression over 36 months
period. Although adherence improved after switching to
second-line ART, it showed to be the most important
factor associated with virologic outcome. Efforts are
needed to ensure durability of adherence and hence
viral suppression. Persons with history of IDU can fully
benefit from second-line ART.
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